InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

ConditionsCancer Risk Cancer Predisposition Syndrome Hereditary Cancer Prediction Childhood Cancer Survivors Adult Cancer Survivors IARC Carcinogens Smoking History Lung Cancer Ductal/Lobular Carcinoma Barrett Esophagus Pancreatic Precursor Lesions Colonic Dysplasia/Adenomata Non-Alcoholic Fatty Liver Disease Non Alcoholic Steatohepatitis Cirrhosis High Grade Prostatic Epithelial Neoplasia High-grade Bladder Urothelial Dysplasia/Carcinoma in Situ Adenomatous Hyperplasia High-risk Oral Precancerous Diseases Melanocytic Lesion, Adult Hematologic Malignancy Lung; Node Serous Tubal Intraepithelial Carcinoma Endometrial Intraepithelial Neoplasia Cervical and Endocervical Carcinoma in Situ Vulvar Intraepithelial Neoplasia Nephrogenic Rests Benign Bone Lesions With Risk of Malignant Degeneration Giant Cell Tumor Osteochondroma Spitz Nevus

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

AgeNot listed

SponsorDana-Farber Cancer Institute

About this trial

This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member who has a family member with a precursor condition for cancer.

* The objective of this study is to identify exposures as well as clinical, molecular, and pathological changes that can be used to predict early development of cancer, malignant transformation, and risks of progression to symptomatic cancer that can ultimately be fatal. * The ultimate goal is to identify novel markers of early detection and risk stratification to drive potential therapeutic approaches to intercept progression to cancer.

Eligibility criteria

Qualifiers

Carriers of known or previously unrecognized pathogenic germline variants of cancer predisposing genes

Individuals with personal or family history suggestive of elevated cancer risk (this may include individuals who have negative genetic testing results or have not elected to undergo testing)

Individuals with a clinically based diagnosis of a Cancer Predisposition Syndrome (examples, neurofibromatosis, Fanconi Anemia, Ataxia-Telangiectasia)

Hereditary Cancer Prediction Model-based elevated cancer risk

Disqualifiers

None

Trial design

Treatments tested in this trial

Samples

Treatment groups

5,000 Participants

are divided into 4 treatment groups

Sponsors and collaborators

Dana-Farber Cancer Institute

Lead sponsor

Source ClinicalTrials.gov